211 related articles for article (PubMed ID: 27494888)
1. The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition.
Ivanova H; Ritaine A; Wagner L; Luyten T; Shapovalov G; Welkenhuyzen K; Seitaj B; Monaco G; De Smedt H; Prevarskaya N; Yule DI; Parys JB; Bultynck G
Oncotarget; 2016 Aug; 7(34):55704-55720. PubMed ID: 27494888
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the ryanodine receptor by anti-apoptotic Bcl-2 is independent of its BH3-domain-binding properties.
Vervliet T; Lemmens I; Welkenhuyzen K; Tavernier J; Parys JB; Bultynck G
Biochem Biophys Res Commun; 2015 Jul; 463(3):174-9. PubMed ID: 25957473
[TBL] [Abstract][Full Text] [Related]
3. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
[TBL] [Abstract][Full Text] [Related]
4. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
Monaco G; Vervliet T; Akl H; Bultynck G
Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 and IP
Ivanova H; Wagner LE; Tanimura A; Vandermarliere E; Luyten T; Welkenhuyzen K; Alzayady KJ; Wang L; Hamada K; Mikoshiba K; De Smedt H; Martens L; Yule DI; Parys JB; Bultynck G
Cell Mol Life Sci; 2019 Oct; 76(19):3843-3859. PubMed ID: 30989245
[TBL] [Abstract][Full Text] [Related]
6. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals.
Rong YP; Aromolaran AS; Bultynck G; Zhong F; Li X; McColl K; Matsuyama S; Herlitze S; Roderick HL; Bootman MD; Mignery GA; Parys JB; De Smedt H; Distelhorst CW
Mol Cell; 2008 Jul; 31(2):255-65. PubMed ID: 18657507
[TBL] [Abstract][Full Text] [Related]
7. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
[TBL] [Abstract][Full Text] [Related]
8. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP
Ivanova H; Luyten T; Decrock E; Vervliet T; Leybaert L; Parys JB; Bultynck G
Cell Calcium; 2017 Mar; 62():41-46. PubMed ID: 28179071
[TBL] [Abstract][Full Text] [Related]
9. Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor.
Monaco G; Decrock E; Nuyts K; Wagner LE; Luyten T; Strelkov SV; Missiaen L; De Borggraeve WM; Leybaert L; Yule DI; De Smedt H; Parys JB; Bultynck G
PLoS One; 2013; 8(8):e73386. PubMed ID: 24137498
[TBL] [Abstract][Full Text] [Related]
10. Allosteric cross-talk between the hydrophobic cleft and the BH4 domain of Bcl-2 in control of inositol 1,4,5-trisphosphate receptor activity.
Shapovalov G; Ritaine A; Essonghe NC; de Ridder I; Ivanova H; Karamanou S; Economou A; Bultynck G; Skryma R; Prevarskaya N
Explor Target Antitumor Ther; 2022; 3(3):375-391. PubMed ID: 36045908
[TBL] [Abstract][Full Text] [Related]
11. Tracing the evolutionary history of Ca
Rosa N; Shabardina V; Ivanova H; Sebé-Pedrós A; Yule DI; Bultynck G
Biochim Biophys Acta Mol Cell Res; 2021 Nov; 1868(12):119121. PubMed ID: 34400171
[TBL] [Abstract][Full Text] [Related]
12. Targeting Bcl-2-IP
Distelhorst CW
Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation.
Vervliet T; Parys JB; Bultynck G
Biochem Soc Trans; 2015 Jun; 43(3):396-404. PubMed ID: 26009182
[TBL] [Abstract][Full Text] [Related]
14. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
Monaco G; La Rovere R; Karamanou S; Welkenhuyzen K; Ivanova H; Vandermarliere E; Di Martile M; Del Bufalo D; De Smedt H; Parys JB; Economou A; Bultynck G
FEBS J; 2018 Jan; 285(1):127-145. PubMed ID: 29131545
[TBL] [Abstract][Full Text] [Related]
15. Bcl-xL acts as an inhibitor of IP
Rosa N; Ivanova H; Wagner LE; Kale J; La Rovere R; Welkenhuyzen K; Louros N; Karamanou S; Shabardina V; Lemmens I; Vandermarliere E; Hamada K; Ando H; Rousseau F; Schymkowitz J; Tavernier J; Mikoshiba K; Economou A; Andrews DW; Parys JB; Yule DI; Bultynck G
Cell Death Differ; 2022 Apr; 29(4):788-805. PubMed ID: 34750538
[TBL] [Abstract][Full Text] [Related]
16. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
Akl H; Monaco G; La Rovere R; Welkenhuyzen K; Kiviluoto S; Vervliet T; Molgó J; Distelhorst CW; Missiaen L; Mikoshiba K; Parys JB; De Smedt H; Bultynck G
Cell Death Dis; 2013 May; 4(5):e632. PubMed ID: 23681227
[TBL] [Abstract][Full Text] [Related]
17. Constitutive IP
Bittremieux M; La Rovere RM; Akl H; Martines C; Welkenhuyzen K; Dubron K; Baes M; Janssens A; Vandenberghe P; Laurenti L; Rietdorf K; Morciano G; Pinton P; Mikoshiba K; Bootman MD; Efremov DG; De Smedt H; Parys JB; Bultynck G
Cell Death Differ; 2019 Mar; 26(3):531-547. PubMed ID: 29899382
[TBL] [Abstract][Full Text] [Related]
18. Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP
Distelhorst CW; Bootman MD
Cold Spring Harb Perspect Biol; 2019 Sep; 11(9):. PubMed ID: 31110129
[TBL] [Abstract][Full Text] [Related]
19. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.
Rong YP; Barr P; Yee VC; Distelhorst CW
Biochim Biophys Acta; 2009 Jun; 1793(6):971-8. PubMed ID: 19056433
[TBL] [Abstract][Full Text] [Related]
20. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
Akl H; La Rovere RM; Janssens A; Vandenberghe P; Parys JB; Bultynck G
Int J Dev Biol; 2015; 59(7-9):391-8. PubMed ID: 26260683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
